COMPANY:

Exai Bio

"Exai Bio...announced a peer-reviewed publication about its generative AI model in Nature Communications. The paper entitled 'Deep generative AI models analyzing circulating orphan non-coding RNAs enable detection of early-stage lung cancer' demonstrates that Exai’s generative AI model surpasses commonly used machine learning methods in overall lung cancer detection performance. Exai’s platform achieved higher overall sensitivity and specificity for cancer detection across all stages, beating the performance of other methods on held-out validation datasets by 30%."

"Exai Bio today announced new breast cancer data at the American Association for Cancer Research (AACR) 2024 annual meeting. In a new study, Exai’s novel RNA- and AI-based liquid biopsy platform demonstrated stage I breast cancer detection sensitivity of 90% and ductal carcinoma in situ (DCIS) sensitivity of 88%, both at 90% specificity. In addition, the study showed the platform’s unique capability to distinguish low grade, less aggressive DCIS from invasive breast cancer with 87% sensitivity, at 90% specificity using a standard blood sample....In addition, Exai announced results from a new breast cancer molecular residual disease (MRD) study conducted in collaboration with the University of Kansas Medical Center. The study demonstrated that Exai’s tumor-naive platform...can accurately predict survival in the post-adjuvant setting for patients with triple negative breast cancer."

"Exai Bio...announced new data demonstrating that its novel RNA-based and AI-driven liquid biopsy platform can detect breast cancer at the earliest stages and the smallest tumor sizes, including ductal carcinoma in situ (DCIS), using a standard blood sample. In a new early detection study building upon prior data, stage I breast cancer sensitivity was 87% and tumor size T1a-b (10 mm or smaller) sensitivity was 81%, both at 90% specificity."

"Exai Bio...announced non-small cell lung cancer (NSCLC) data further validating that its novel RNA- and generative AI-based liquid biopsy platform detected early-stage disease with high accuracy. The study of nearly 900 subjects demonstrated stage I sensitivity was 95% at 90% specificity. The use of Exai’s proprietary generative AI technology, derived from large independent datasets of tumor and blood samples, enhanced both sensitivity and specificity beyond what is achievable using standard machine learning techniques."

"Exai Bio...announced new data from a 3,300 subject study demonstrating that its novel RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, standard blood sample. Notably, Exai’s platform maintained high sensitivity and specificity in both independent training and testing cohorts, highlighting the strength of its unique generative AI technology. In the independent testing cohort, overall stage I sensitivity across eight cancer types was 87% at 95% specificity. These data will be presented at a poster session today at the American Society for Clinical Oncology (ASCO) 2023 annual meeting."

"Exai Bio today announced new data demonstrating that its novel RNA- and AI-based platform detected non-small cell lung cancer with high accuracy, at the earliest stages and for the smallest tumors, in both training and validation cohorts. In the independent validation cohort, stage I sensitivity was 96% and tumor size T1a-b sensitivity was 94%, at 90% specificity. These findings continue to highlight the power of Exai's proprietary technology to detect cancer at its earliest stages from a blood draw."

"Exai Bio today announced a collaboration agreement with Quantum Leap Healthcare Collaborative™ (QLHC) to broaden the use of Exai’s novel, RNA-based liquid biopsy platform to monitor patients’ treatment response and disease burden in the I-SPY 2 TRIAL. The expanded agreement is based on positive initial data using Exai’s platform in the trial, which demonstrated that oncRNAs were a significant predictor of patient outcomes....This next phase of the collaboration is expected to increase the evidence for oncRNAs as a predictor of clinical outcomes and measurement of treatment response in a larger cohort of patients and across more therapies within I-SPY 2."

"Researchers at Exai Bio and UCSF have released data demonstrating that Exai’s novel, RNA-based liquid biopsy platform accurately detected breast cancer at the earliest stages and for the smallest tumors....In a poster...presented at the 2022 San Antonio Breast Cancer Symposium, Exai demonstrated that oncRNA biomarkers in blood, combined with machine learning, detected breast cancer with high accuracy overall, including across all cancer stages and tumor sizes. The poster also showed that even at the earliest stages and smallest tumors, sensitivity was greater than 80% at 95% specificity. These findings suggest that Exai’s liquid biopsy test for earlier detection of cancer will improve care and outcomes for cancer patients."

"This case-control study of 191 subjects demonstrated that Exai’s novel, RNA-based platform accurately predicted colorectal cancer (CRC) cases versus non-cancer controls, both overall and across the full ranges of cancer stages and categories of tumor size/extent....In the present poster, the Exai oncRNA-based model, which used machine learning, predicted CRC with a high overall sensitivity of 90.6% at 90% specificity. Predictions were also accurate for stage I cancer (92% sensitivity) and for the lowest categories of tumor size/extent, T1/T2 (92.3% sensitivity), indicating that even the earliest stage cancers and smallest tumors were detectable."

"Exai Bio...is presenting today data from its scientific research program on the discovery and validation of tumor-specific, orphan non-coding RNAs (oncRNAs), and the validation of artificial intelligence (AI) profiling of oncRNAs to accurately detect cancers of diverse tissue origins...Title: Discovery and validation of orphan noncoding RNA profiles across multiple cancers in TCGA and two independent cohorts"

"Liquid biopsy test developer Exai Bio said Thursday that it has closed a $67.5 million Series A financing round to accelerate development of an RNA-based liquid biopsy platform for early cancer detection...San Francisco-based Exai Bio said its testing platform enables early diagnosis of cancer from blood samples to inform personalized treatments."